What's happening
Reference profile
Generated 13:15 ET
PDSB — PDS Biotechnology Corporation Common Stock is down 14.2%, at 0.97, on $5.9M traded, 0.12× float rotation. Score 62. Primary driver: 11.6% float rotation. Supply intelligence: mixed supply · 48.
Get alerts on $PDSB
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
52.4M
2026-08-14
Shares out
56.0M
latest detail
Market cap
$63.2M
at ref price
Short interest
5.3%
2026-09-30
Float rotation
0.12×
latest snapshot
20d dollar vol
$14.5M
baseline
Gap quality
mixed supply · 48
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
microcap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-10-19 13:15 ETSignalPDS Biotechnology Corporation Common Stock is down 14.2%, at 0.97, on $5.9M traded, 0.12× float rotation. Score 62. Primary driver: 11.6% float rotation. Supply intelligence: mixed supply · 48.
2026-09-30 04:54 ETFDA / ClinicalHead and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care News
2026-09-148-KItem 1.02 — Termination of a material definitive agreement; Item 5.02 — Director or officer departure/election/appointment +1 more SEC
2026-09-088-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-07-21 13:00 ETEarnings GuidanceCorrection: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight News
2026-07-13 13:00 ETEarnings GuidanceHead and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight News
2026-01-12 10:35 ETFDA / ClinicalFast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 News
Latest detector signalscore 62